Patents by Inventor Paul A. Levine

Paul A. Levine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220284266
    Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for computing Q values for actions to be performed by an agent interacting with an environment from a continuous action space of actions. In one aspect, a system includes a value subnetwork configured to receive an observation characterizing a current state of the environment and process the observation to generate a value estimate; a policy subnetwork configured to receive the observation and process the observation to generate an ideal point in the continuous action space; and a subsystem configured to receive a particular point in the continuous action space representing a particular action; generate an advantage estimate for the particular action; and generate a Q value for the particular action that is an estimate of an expected return resulting from the agent performing the particular action when the environment is in the current state.
    Type: Application
    Filed: March 25, 2022
    Publication date: September 8, 2022
    Inventors: Shixiang Gu, Timothy Paul Lillicrap, Ilya Sutskever, Sergey Vladimir Levine
  • Patent number: 10555907
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: February 11, 2020
    Assignee: Santarus, Inc.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Patent number: 10421954
    Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 24, 2019
    Assignee: NEW YORK UNIVERSITY
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Publication number: 20190231699
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Application
    Filed: August 31, 2018
    Publication date: August 1, 2019
    Applicant: Santarus, Inc.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Patent number: 10071058
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: September 11, 2018
    Assignee: Santarus, Inc.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Patent number: 9969773
    Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 15, 2018
    Assignee: NEW YORK UNIVERSITY
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Publication number: 20170015991
    Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Patent number: 9511221
    Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: December 6, 2016
    Assignee: PACESETTER, INC.
    Inventors: Xing Pei, Robert E. Smith, Jr., Paul A. Levine
  • Patent number: 9458449
    Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
    Type: Grant
    Filed: May 20, 2014
    Date of Patent: October 4, 2016
    Assignee: New York University
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Patent number: 9238136
    Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: January 19, 2016
    Assignee: PACESETTER, INC.
    Inventors: Xing Pei, Robert E. Smith, Jr., Paul A. Levine
  • Publication number: 20150299254
    Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.
    Type: Application
    Filed: April 16, 2015
    Publication date: October 22, 2015
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Publication number: 20150151132
    Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Application
    Filed: February 12, 2015
    Publication date: June 4, 2015
    Inventors: Xing Pei, Robert E. Smith, JR., Paul A. Levine
  • Publication number: 20150151119
    Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Application
    Filed: February 12, 2015
    Publication date: June 4, 2015
    Inventors: Xing Pei, Robert E. Smith, JR., Paul A. Levine
  • Patent number: 9008774
    Abstract: An exemplary method includes performing a capture threshold assessment using a bipolar electrode configuration, deciding if capture occurred for a maximum energy value of the capture threshold assessment and, if capture did not occur, then performing a lead impedance test for the lead associated with the bipolar electrode configuration. Such a test may aim to detect an insulation defect and/or a conductor defect. Other exemplary methods, devices, systems, etc., are also disclosed.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: April 14, 2015
    Assignee: Pacesetter, Inc.
    Inventors: Xing Pei, Robert E. Smith, Jr., Paul A. Levine
  • Publication number: 20150056275
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-release solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention relates to a method of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowel disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 26, 2015
    Applicant: SANTARUS, INC.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Publication number: 20150044189
    Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.
    Type: Application
    Filed: May 20, 2014
    Publication date: February 12, 2015
    Inventors: Kent Kirshenbaum, Paul Levine, Timothy Craven
  • Patent number: 8788027
    Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: July 22, 2014
    Assignee: Pacesetter, Inc.
    Inventors: Xing Pei, Paul A. Levine
  • Publication number: 20140172033
    Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.
    Type: Application
    Filed: February 21, 2014
    Publication date: June 19, 2014
    Applicant: PACESETTER, INC.
    Inventors: Xing Pei, Paul A. Levine
  • Patent number: 8694082
    Abstract: An implantable medical device is provided for detecting transportless ventricular rhythm of a heart lacking atrial transport and comprises a housing, sensors configured to be located proximate to a heart, a sensing module to sense cardiac signals representative of a rhythm originating from the heart and a rhythm detection module. The rhythm detection module determines a change in AV association and identifies a potential ventricular complex with loss of atrial transport (VCLAT) based on the change in AV association.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: April 8, 2014
    Assignee: Pacesetter, Inc.
    Inventors: Xing Pei, Paul A. Levine
  • Publication number: 20130331900
    Abstract: A triggered mode pacing system enables dual chamber sensing. The system also determines whether a cardiac event is initially sensed in a first cardiac chamber or a second cardiac chamber. The system then triggers an output to the second cardiac chamber in response to sensing the cardiac event in the first cardiac chamber when the cardiac event was determined to have been initially sensed in the first cardiac chamber.
    Type: Application
    Filed: November 16, 2012
    Publication date: December 12, 2013
    Applicant: PACESETTER, INC.
    Inventor: Paul A. Levine